Topical ketorolac tromethamine in the reduction of adverse effects of laser in situ keratomileusist.
To evaluate whether topical ketorolac tromethamine can reduce the adverse effect of laser in situ keratomileusis (LASIK). A prospective randomized controlled clinical study. Nineteen patients who underwent bilateral simultaneous LASIK performed at Siriraj Hospital. Patients received two drops of ketorolac tromethamine in one eye immediately after surgery. Symptoms of tearing, photophobia, foreign body sensation and pain were evaluated at 30 minutes, 6 hours and 24 hours. There was no statistically significant difference in symptoms at 30 minutes. At 6 and 24 hours, ketorolac-treated eyes had significantly fewer symptoms compared to non-treated eyes. Ketorolac tromethamine reduces some unfavorable symptoms within the first 24 hours after LASIK.